Trials / Completed
CompletedNCT03550950
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and tolerability of JNJ-64232025 following single ascending intravenous (IV) study intervention administrations and a single subcutaneous (SC) intervention administration in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-64232025 IV | JNJ-64232025 will be administered as IV infusion. |
| DRUG | JNJ-64232025 SC | JNJ-64232025 will be administered as SC injection. |
| DRUG | Placebo | Matching placebo will be administered as IV infusion or SC injection. |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2019-02-05
- Completion
- 2019-02-05
- First posted
- 2018-06-11
- Last updated
- 2025-02-03
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03550950. Inclusion in this directory is not an endorsement.